Knowledge Library
PD-1 Blockade Protein in 4th Generation Armored CAR-T Cells Enhances Cytotoxicity Effect with in vitro Re-challenge System
Chimeric antigen receptor (CAR)-T cells are genetically engineered T cells that express a surface receptor to recognize tumor-associated antigens (TAA). CAR-T cell therapy have demonstrated remarkable success with hematological malignancies. However, limited headway has been made towards solid tumor, due to various challenges, including recognition of tumor-specific antigen trafficking and penetration, localization and survival within …Read More >
WuXi AppTec Discovery Services
Delivering comprehensive end-to-end solutions for creating, identifying, and supporting preclinical candidates, from discovery to development, with our integrated chemistry and biology research platforms.
CAR-T TCR-T
Integrated Platforms To Accelerate CAR-T/TCR-T Programs Comprehensive target validation program OXGENE based target expression system ensure high-efficiency delivery Systematic in vitro functional & safety assays in vivo efficacy studies Well-established genomic editing technology in primary immune cells
Clinical Virology
Clinical Virology and Advanced Therapy Platforms Research Services: CAP Accredited Molecular Testing Laboratory Genomics and Biomarker Platform HBV Genotyping Assays HBV Serology Assays HBV Phenotyping Assays Immunological Assays Other Assays: Oncolytic | CAR-T/TCR-T Particular Solutions Clinical virology: Viral load, sequencing, genotyping, TCID50, phenotyping, virus isolation and characterization, serology Vaccines: Advanced therapies (Viral vector and cell therapies): …Read More >